Health Canada approves Novo Nordisk's obesity drug to reduce risk of non-fatal heart attack
Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...
Dell Could Be Poised to Benefit From AI Boom, Despite 'Messy' Results, Analysts Say
Key Takeaways Dell Technologies shares plunged Wednesday after the company reported third-quarter revenue that missed Wall ...
Six deny any part in plan to murder cocaine user
Six defendants in a murder trial have denied being part of any plan to kill or cause serious harm to a man found dead in his ...
bovnews56m
The Replimune Group Inc Stock Thriller: Decoding the Mystery Behind REPL’s Recent Movements
On Tuesday, Replimune Group Inc (REPL) stock saw a modest uptick, ending the day at $14.38 which represents a slight increase of $1.12 or 8.45% from the prior close of $13.26. The stock opened at $13.